NovoCure Limited · NASDAQ:NVCR

NovoCure — Q4 2023 Earnings Presentation

14 slides from NovoCure's earnings presentation, February 2024

  1. Slide 1: Q4 2023 Earnings

    Novocure Q4 2025 Earnings forward’

  2. Slide 2: Forward-looking statements

    novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding a

  3. Slide 3: Operational execution and accomplishment with clear opportunities ahead

    novecure’ operational execution and accomplishment with clear opportunities anead 2023 was a solid year of achievement across commercial, clinical and product development programs Core objectives for 2024 are to grow GBM business, launch in lung cancer and deliver on pipeline oo ee e ° patientforwar

  4. Slide 4: 2023 achievements and 2024 milestones ahead

    2025 achievements and 2024 milestones ahead DRIVING COMMERCIAL ADVANCING ADOPTION CLINICAL TRIALS 2023 France reimbursement LUNAR data presented New array launched ACHIEVEMENTS — achieved and launch LUNAR U.S. FDA PMA, CE Mark in Europe and Japanese PMDA submitted New array FDA PMA METIS enrollment

  5. Slide 5: Three focused objectives in 2024

    three focused objectives in 2024 JY{OPTUNE cio” LAUNCH LUNG DELIVER PIPELINE \ SESa ss forward’ GEM, alioblastoma

  6. Slide 6: Real-world evidence demonstrates long and durable survival benefit with Optune Gio

    novecure’ real-world evidence demonstrates long and durable survival benefit with Optune Gio, consistent with EF-14 il eee OVERALL SURVIVAL FOR U.S. PATIENTS FROM OPTUNE GIO START (N=974) 4 1% e) POST-PROGRESSION SURVIVAL FOR PATIENTS CONTINUING OPTUNE GIO (N=59)4 24% ar) mee (10 LOXICILy INCREASE O

  7. Slide 7: Preparing for 2024 NSCLC launch

    novecure’ preparing for 2024 NSCLC launch b, 2023 5 2024 2025 L COMMERCIAL LAUNCH REGULATORY PATHWAY v HCP and patient campaigns y, a : ; v DTC campaign CLINICAL DATA Technical file submitted in EU V Global advisory boards v¥ PMA accepted for review at FDA v Announced top-line results . ; v KOL enga

  8. Slide 8: Lung cancer clinical trial pipeline

    PHASE 3 METIS TTFields monotherapy treating brain metastases NON-SMALL CELL from Nscic LUNG CANCER LUNAR-2 TTFields + pembrolizumab + chemot treating 1L metastatic NSCLC PHASE 2 KEYNOTE-B36 TTFields therapy + pembrolizumab treating 1L advanced or metastatic NSCL' LUNAR-4 TTFields + ICI treating 2L m

  9. Slide 9: Q4 2023 selected financial highlights

    novecure’ q4 2025 selected financial highlights U.S. DOLLARS IN THOUSANDS Q4 2023 Q4 2022 % CHANGE Net revenues S 133,784 S 128,429 4% Cost of revenues 32,556 28,888 13% Gross profit 101,228 99,541 2% Research, development and clinical expenses 54,308 54,820 -1% Sales and marketing 59,188 49,629 19%

  10. Slide 10: Together with our patients, we strive to extend survival

    together with our patients, we Strive to extend survival in some of the most aggressive forms of cancer patientforward” GmbH 10

  11. Slide 11: Optune Lua and Optune Gio indications for use and important safety information

    novecure’ Optune Lua® and Optune Gio® indications for use and important safety information INDICATIONS + Optune Gio is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM) o Optune Gio with temozolomide is indicated for the

  12. Slide 12: Optune Lua and Optune Gio indications for use and important safety information

    novecure’ Optune Lua® and Optune Gio® indications for use and important safety information WARNINGS AND PRECAUTIONS * Optune Gio and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adver

  13. Slide 13: Appendix

    novecure’ appendix patientforward’

  14. Slide 14: Adjusted EBITDA reconciliation

    novocure adjusted EBITDA reconciliation Adjusted EBITDA is a non-GAAP measurement of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare

Novocure — Q4 2023 Earnings Presentation on 6ix